Dr. Ningjing Lin 林宁晶
Chief Physician
Department of Lymphoma, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of malignant lymphoma.
Dr. Lin is a Chief Physician in the Lymphoma Department at Peking University Cancer Hospital. With over 20 years of experience in medical oncology, Dr. Lin focuses on the diagnosis, treatment, and translational research of lymphoma.
Name order: in Chinese the family name comes first (Lin Ningjing). Papers usually list the name as Ningjing Lin or Lin N.
Selected publications
58 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Adv Ther, 2026 (first author): Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study. PubMed 42496861
- Haematologica, 2025 (first author): Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial. PubMed 39234866
- J Cancer Res Ther, 2024 (first author): Efficacy and safety of standard BEACOPP regimen versus ABVD regimen for treatment of advanced Hodgkin's lymphoma. PubMed 39206988
- Eur J Cancer, 2022 (first author): Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study. PubMed 34462189
- Chin J Cancer Res, 2020 (first author): Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives. PubMed 32694896
- Oncologist, 2019 (first author): Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type. PubMed 30940744
- Zhonghua Xue Ye Xue Za Zhi, 2015 (first author): [Non-upper aerodigestive tract NK/T- cell lymphoma: an analysis of clinical features and survival from a single center in China]. PubMed 25641142
- Mol Cancer Res, 2012 (first author): Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma. PubMed 22241217
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion